Drug approvals Tag

Hay señales de que un fármaco experimental podría frenar una forma de ELA

VIERNES, 23 de septiembre de 2022 (HealthDay News) — Las personas con una rara forma genética de la ELA quizá se beneficien del uso extendido de un medicamento bajo investigación, muestra un estudio reciente.El fármaco, tofersen, benefició a los paci…

Hints That Experimental Drug Might Curb a Form of ALS

FRIDAY, Sept. 23, 2022 (HealthDay News) — People with a rare genetic form of ALS may benefit from extended use of an investigational drug, a new study shows.The medication, tofersen, benefited patients with mutations of the gene SOD1. These mutations…

FDA Approves SPEVIGO for Generalized Pustular Psoriasis Flares

TUESDAY, Sept. 6, 2022 (HealthDay News) — The U.S. Food and Drug Administration has approved SPEVIGO (spesolimab-sbzo) as the first treatment option for generalized pustular psoriasis (GPP) flares in adults.SPEVIGO is a novel, selective antibody infu…

FDA Approves First Treatment for Acid Sphingomyelinase Deficiency

FRIDAY, Sept. 2, 2022 (HealthDay News) — The U.S. Food and Drug Administration has approved Xenpozyme (olipudase alfa) for pediatric and adult patients with acid sphingomyelinase deficiency (ASMD), a rare genetic disease.ASMD is caused by the lack of…

FDA Approves Imbruvica for Pediatric Chronic Graft Versus Host Disease

FRIDAY, Aug. 26, 2022 (HealthDay News) — The U.S. Food and Drug Administration has approved Imbruvica (ibrutinib) for pediatric patients with chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy.

The ap…

Tabrecta Gains Full FDA Approval for Non-Small Cell Lung Cancer

MONDAY, Aug. 15, 2022 (HealthDay News) — The U.S. Food and Drug Administration granted regular approval to capmatinib (Tabrecta) for adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a genetic mutation leading to m…

FDA Approves First Targeted Therapy for HER2-Low Breast Cancer

MONDAY, Aug. 8, 2022 (HealthDay News) — The U.S. Food and Drug Administration has approved Enhertu (am-trastuzumab-deruxtecan-nxki), an intravenous infusion treatment for patients with unresectable or metastatic human epidermal growth factor receptor…